[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657979":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":11,"studyPopulation":36,"armGroups":11,"interventions":11,"overallOfficials":37,"centralContacts":41,"locations":46,"responsibleParty":64,"collaborators":11,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":11,"maxAge":74,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":11,"briefSummary":79,"conditions":80,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Survival at 1 year",null,"1-year post-transplant",[14,17,21,24,27,30],{"measure":15,"description":16,"timeFrame":12},"sJIA clinical remission","Proportion achieving clinical remission\u002F inactive diasease at 1 year",{"measure":18,"description":19,"timeFrame":20},"Corticosteroid and biologic independence","Time to discontinuation of corticosteroids and biologic therapy following HCT.","Time Frame: 1-year post-transplant",{"measure":22,"description":23,"timeFrame":12},"Graft Failure","Incidence of primary and secondary graft failure following HCT.",{"measure":25,"description":26,"timeFrame":12},"Acute and Chronic Graft-Versus-Host Disease (GVHD)","Incidence and severity of acute and chronic GVHD following HCT.",{"measure":28,"description":29,"timeFrame":12},"Transplant-Related Mortality","Incidence of mortality attributable to transplant-related complications.",{"measure":31,"description":32,"timeFrame":12},"Pulmonary Outcomes in Participants With sJIA-LD","Changes in pulmonary disease following HCT, assessed using pulmonary function testing and physician global assessment of lung disease (PGALD).",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":34,"timePerspective":35,"maskingInfo":11},"COHORT","PROSPECTIVE","Children and young adults \\\u003C35 years of age with longstanding Systemic Juvenile Idiopathic Arthritis diagnosed in childhood will be enrolled if they meet the eligibility criteria below. Patients with Systemic Juvenile Idiopathic Arthritis associated lung disease are included and will be specifically evaluated.",[38],{"name":39,"affiliation":5,"role":40},"Sharat Chandra, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":39,"role":43,"phone":44,"phoneExt":11,"email":45},"CONTACT","513-636-5917","Sharat.Chandra@cchmc.org",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Cincinnati Children's Hospital Medical Center","RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-84.51439,39.12711,{"lat":59,"lon":58},[62,63],{"name":39,"role":43,"phone":44,"phoneExt":11,"email":45},{"name":39,"role":40,"phone":11,"phoneExt":11,"email":11},{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657979","allogeneic-hematopoietic-cell-transplantation-for-refractory-systemic-juvenile-idiopathic-arthritis-100657979",false,"NCT07845942","Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.","Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis: A Single-Center Prospective Trial","Inclusion Criteria:\n\n* Patients \\\u003C35 years of age are eligible, and participants must meet all the following criteria to be eligible for this study:\n* Diagnosis: Systemic Juvenile Idiopathic Arthritis (sJIA) diagnosed prior to age 16, fulfilling ILAR classification criteria for sJIA or the provisional PRINTO criteria for systemic arthritis. The diagnosis and disease course must be reviewed and confirmed by a pediatric rheumatologist.\n* Refractory Disease: sJIA that is refractory to standard therapy, defined as meeting at least one of these conditions despite appropriate treatment:\n* Persistent JIA activity: Ongoing active disease (e.g. uncontrolled arthritis or systemic features such as fever, rash, organ inflammation) or progressive joint damage or liver dysfunction that has not responded to biologic agents (IL-1\u002FIL-6 inhibitors) and conventional therapies, or inability to wean from high-dose corticosteroids (steroid dependence).\n* Recurrent MAS: Two or more episodes of macrophage activation syndrome within a 2-year period, indicating a failure to control the hyperinflammation with medical management. (MAS is defined by clinical and laboratory criteria such as fever, cytopenias, hyperferritinemia, hemophagocytosis, etc., per standard definitions.)\n* sJIA-LD: Presence of lung disease related to sJIA, either symptomatic LD (e.g. chronic cough, tachypnea, hypoxemia) or progressive LD on imaging (worsening interstitial changes), meeting clinical\u002Fimaging features such as patchy ground-glass opacities, septal and pleural thickening, or clubbing of digits. sJIA-LD should be confirmed by a pulmonologist\u002Fradiologist (e.g. HRCT findings).\n\nExclusion Criteria:\n\n* Uncontrolled Infection: Presence of a severe, uncontrolled infection at time of enrollment (e.g. sepsis, pneumonia not responding to therapy).\n* Significant Organ Failure:\n* Cardiac: EF \\\u003C 40%\n* Renal: GFR \\\u003C 30 ml\u002Fhr\n* Active Malignancy: Concurrent cancer diagnosis or history of malignant disease requiring active treatment.\n* Pregnancy or Lactation: Female patients who are pregnant or breastfeeding. Female participants of childbearing potential must have a negative pregnancy test clinical result at screening (pregnancy testing is done as standard of care for all transplant patients).","ALL","35 Years",{"count":76,"type":77},20,"ESTIMATED","OBSERVATIONAL","The goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic Arthritis (sJIA), including those with sJIA-associated lung disease (sJIA-LD).",[81,82,83],"Refractory Systemic Juvenile Idiopathic Arthritis","Systemic Juvenile Idiopathic Arthritis","Systemic Juvenile Idiopathic Arthritis Associated Lung Disease","2026-09-22",{"date":86,"type":87},"2026-09-29","ACTUAL",{"date":89,"type":77},"2026-11",{"date":91,"type":77},"2031-07",{"name":5,"class":6},1]